There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Illumina (ILMN – Research Report) and IDEAYA Biosciences (IDYA – Research Report) with bullish sentiments.
Illumina (ILMN)
Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Illumina yesterday and set a price target of $160.00. The company’s shares closed last Tuesday at $133.74.
According to TipRanks.com, Arias ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $155.06, which is a 13.6% upside from current levels. In a report issued on February 9, Piper Sandler also maintained a Buy rating on the stock with a $190.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
IDEAYA Biosciences (IDYA)
In a report released yesterday, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on IDEAYA Biosciences, with a price target of $55.00. The company’s shares closed last Tuesday at $44.75, close to its 52-week high of $46.86.
According to TipRanks.com, Burnett is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IDEAYA Biosciences with a $48.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ILMN:
